[EN] SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5<br/>[FR] INHIBITEURS DE CDK5 DE TYPE 1,6-NAPHTYRIDINE SUBSTITUÉE
申请人:GOLDFINCH BIO INC
公开号:WO2022011274A1
公开(公告)日:2022-01-13
Disclosed are compounds having structural formula I, and related salts and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating diseases and conditions such as kidney disease, kidney failure, kidney stones, or polycystic kidney disease, using the compounds of formula (I), and related salts and pharmaceutical compositions.
[EN] 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4, 3-B]INDOLE INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES<br/>[FR] 2,3,4,5-TÉTRAHYDRO-1H-PYRIDO[4,3-B]INDOLES INHIBITEURS DE CGAS UTILISÉS POUR LE TRAITEMENT DE MALADIES AUTO-INFLAMMATOIRES
申请人:LAMA LODOE
公开号:WO2019153002A1
公开(公告)日:2019-08-08
1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
申请人:Board of Regents, The University of Texas System
公开号:US20210094951A1
公开(公告)日:2021-04-01
Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.